Biography and Research Information
OverviewAI-generated summary
Susan Panozzo's research centers on the treatment and long-term outcomes of multiple myeloma. Her work involves analyzing data from clinical trials, including the "Total Therapy" protocols, to evaluate treatment efficacy and patient survival. Publications include investigations into maintenance therapy with VRD (bortezomib, lenalidomide, dexamethasone) and the impact of adding bortezomib and thalidomide to melphalan transplants for patients with adverse metaphase cytogenetics. Panozzo has a publication record of 30 works with 426 citations and an h-index of 6. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including Clyde Bailey, Michele Cottler-Fox, Shmuel Yaccoby, and Erming Tian, on multiple shared publications.
Metrics
- h-index: 6
- Publications: 30
- Citations: 430
Selected Publications
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)
-
Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma (2023)
Collaboration Network
Top Collaborators
Maurizio Zangari
University of Arkansas for Medical Sciences
10 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 10 shared publications
Clyde Bailey
University of Arkansas for Medical Sciences
10 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 10 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
10 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 10 shared publications
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
9 shared publications
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 9 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
9 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 9 shared publications
Michele Cottler‐Fox
University of Arkansas for Medical Sciences
7 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 7 shared publications
Yogesh Jethava
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Alan Mitchell
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Joshua Epstein
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Shmuel Yaccoby
6 shared publications
In database
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Erming Tian
6 shared publications
In database
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Sarah Waheed
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Rashid Khan
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Xenofon Papanikolaou
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Monica Grazziutti
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Frits Vanrhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Jaskirat S Sethi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Yarlagadda Lakshmi S
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Health Disparities and Outcomes
Kristin Kampevold Larsen
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Anup Kumar Trikannad Ashwini Kumar
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Health Disparities and Outcomes
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation